Trials / Completed
CompletedNCT00306514
Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients
A Phase IIa Study to Evaluate Safety, Tolerability, and Immunogenicity of a Melan-A VLP Vaccine in HLA-A2 Positive Patients With Stage III/IV Malignant Melanoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Cytos Biotechnology AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to evaluate whether vaccination with a Melan-A VLP vaccine leads to a specific cellular immune response in patients with malignant melanoma at advanced stage of the disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CYT004-MelQbG10 |
Timeline
- First posted
- 2006-03-24
- Last updated
- 2007-09-20
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00306514. Inclusion in this directory is not an endorsement.